- Home
- Service Center
- DNAzyme Development
DNAzymes are catalytically active DNA molecules that are obtained via in vitro selection. DNAzymes have been extensively studied as therapeutics in vivo since 1999. However until now the high expectations for DNAzymes still have not translated into the clinic practice because of their low effectiveness in vivo. Over the past five years, a growing number of research institutions have begun working to optimize DNAzyme therapeutics to benefit human health.
Figure 1. Schematic of DNAzyme therapeutic research, from early studies to the latest investigations (RCA: rolling circle amplification, CHA: catalytic hairpin assembly, PTT: photothermal therapy, PDT: photodynamic therapy) [1].
In recent years, DNAzymes have mainly been studied for cancer treatment. This is attributed to the vast application of emerging nanotechnologies in the field of cancer research. In addition, DNAzymes have exhibited great potential for downregulating cancer-associated genes. Anticancer DNAzymes make use of the hallmarks of cancer that include self sufficiency in growth signals, insensitivity to growth inhibitory signals, tissue invasion, metastasis, sustained angiogenesis, evasion of apoptosis, and limitless replicative potential to suppress tumor growth. In addition to cancer, research shows that DNAzymes are effective RNA-silencing molecules that may be used to treat a variety of incurable polyglutamine (polyQ) diseases.
Alfa Chemistry provides therapeutic DNAzyme development services, and the following is our main development process.
No matter which stage of DNAzyme development you encounter challenges, we will provide you with timely help.
Alfa Chemistry's expert team consists of experienced scientists. They are committed to delivering high-value medicines through leading-edge research and development technologies that ultimately benefit patients.
Reference
Our products and services are for research use only and cannot be used for any clinical purposes.